TY - JOUR
T1 - Proventil HFA provides bronchodilation comparable to ventolin over 12 weeks of regular use in asthmatics
AU - Bleecker, Eugene R.
AU - Tinkelman, David G.
AU - Ramsdell, Joe
AU - Ekholm, Bruce P.
AU - Klinger, Nancy M.
AU - Colice, Gene L.
AU - Slade, Herbert B.
N1 - Funding Information:
This work was supported by a research grant from 3M Pharmaceuticals, St. Paul, Minn. 3M developed and manufactures the HFA delivery system for Key Pharmaceuticals. Mr. Ekholm, Ms. Klinger, Dr. Colice, and Dr. Slade are full-time employees of 3M. None of the other authors have a financial stake in 3M Corporation. Revision accepted July 28.
PY - 1998
Y1 - 1998
N2 - Objective: To compare the bronchodilator effectiveness of albuterol reformulated in the chlorofluorocarbon-free propellant hydrofluoroalkane (HFA)134a (Proventil HFA) to that of Ventolin and HFA placebo over 12 weeks of regular dosing. Design: Randomized, double-blind, double-dummy, parallel group, placebo-controlled, multicenter trial of asthmatics requiring inhaled β-adrenergic bronchodilators for symptom control. Interventions: Treatment qid with Proventil HFA, Ventolin, or HFA-134a placebo for 12 weeks. Measurements: At weeks 0, 4, 8, and 12, spirometry was performed predose and serially over 6 h after dosing with study drug. Bronchodilator efficacy variables, based on FEV1 response to study drug, were proportion of responders, time to onset of effect, peak percent change, time to peak effect, duration of effect, and area under the curve (AUC). Results: Demographic and baseline characteristics were similar for patients randomized to Proventil HFA (193), Ventolin (186), and HFA-134a placebo (186). No significant differences were found between the Proventil HFA and Ventolin treatment groups for any FEV1 efficacy variable, either predose or during 6 h of serial spirometry, at weeks 0, 4, 8, and 12. For all efficacy variables, except time to onset of effect, the Proventil HFA and Ventolin results were significantly greater than placebo. Time to onset of effect for the HFA-134a placebo group is misleading; only 13 patients (7%) were found to be responders in the intent-to-treat database. These efficacy results were found to be consistent across subgroup analyses of inhaled and nasal corticosteroid use, age (18 to 35 and 36 to 66 years), sex, race, weight (<60, 60 to 100, and >100 kg), and baseline FEV1 (≤55% and >55% predicted). The peak FEV1 effect, duration of FEV1 effect, and AUC for FEV1 were all significantly smaller at weeks 4, 8, and 12 than week 0 for both the Proventil HFA and Ventolin treatment groups. Conclusions: Proventil HFA provided bronchodilation comparable to Ventolin and superior effects to HFA-134a placebo over 12 weeks of regular dosing. There was a diminution in bronchodilator response to both Proventil HFA and Ventolin after 4 weeks of use.
AB - Objective: To compare the bronchodilator effectiveness of albuterol reformulated in the chlorofluorocarbon-free propellant hydrofluoroalkane (HFA)134a (Proventil HFA) to that of Ventolin and HFA placebo over 12 weeks of regular dosing. Design: Randomized, double-blind, double-dummy, parallel group, placebo-controlled, multicenter trial of asthmatics requiring inhaled β-adrenergic bronchodilators for symptom control. Interventions: Treatment qid with Proventil HFA, Ventolin, or HFA-134a placebo for 12 weeks. Measurements: At weeks 0, 4, 8, and 12, spirometry was performed predose and serially over 6 h after dosing with study drug. Bronchodilator efficacy variables, based on FEV1 response to study drug, were proportion of responders, time to onset of effect, peak percent change, time to peak effect, duration of effect, and area under the curve (AUC). Results: Demographic and baseline characteristics were similar for patients randomized to Proventil HFA (193), Ventolin (186), and HFA-134a placebo (186). No significant differences were found between the Proventil HFA and Ventolin treatment groups for any FEV1 efficacy variable, either predose or during 6 h of serial spirometry, at weeks 0, 4, 8, and 12. For all efficacy variables, except time to onset of effect, the Proventil HFA and Ventolin results were significantly greater than placebo. Time to onset of effect for the HFA-134a placebo group is misleading; only 13 patients (7%) were found to be responders in the intent-to-treat database. These efficacy results were found to be consistent across subgroup analyses of inhaled and nasal corticosteroid use, age (18 to 35 and 36 to 66 years), sex, race, weight (<60, 60 to 100, and >100 kg), and baseline FEV1 (≤55% and >55% predicted). The peak FEV1 effect, duration of FEV1 effect, and AUC for FEV1 were all significantly smaller at weeks 4, 8, and 12 than week 0 for both the Proventil HFA and Ventolin treatment groups. Conclusions: Proventil HFA provided bronchodilation comparable to Ventolin and superior effects to HFA-134a placebo over 12 weeks of regular dosing. There was a diminution in bronchodilator response to both Proventil HFA and Ventolin after 4 weeks of use.
KW - Albuterol
KW - Asthma
KW - HFA-134a propellant
UR - http://www.scopus.com/inward/record.url?scp=0031936576&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0031936576&partnerID=8YFLogxK
U2 - 10.1378/chest.113.2.283
DO - 10.1378/chest.113.2.283
M3 - Article
C2 - 9498940
AN - SCOPUS:0031936576
SN - 0012-3692
VL - 113
SP - 283
EP - 289
JO - Diseases of the chest
JF - Diseases of the chest
IS - 2
ER -